We scan new podcasts and send you the top 5 insights daily.
Niagara's control arm had 60% two-year event-free survival versus about 70% in the negative trials. The discussion says this makes Niagara the highest-risk population, where more events and greater risk can let an immune-therapy benefit show up. That may explain more than drug differences alone.
The standard of care for melanoma is improving so quickly that control arms in recent clinical trials are significantly outperforming historical data. This 'rising tide' effect makes it increasingly difficult for new drugs to show a statistically significant benefit, creating high unpredictability for developers.
The control arm in the EMBARK study was blinded to PSA results, preventing physicians from intervening with standard-of-care AR antagonists at PSA progression. This design likely delayed subsequent effective therapies, making the control arm underperform and potentially exaggerating the overall survival benefit of the experimental arms.
The belief that immune-related adverse events (irAEs) predict better response to immunotherapy is likely confounded by survival bias. Patients must remain on treatment long enough to both respond and develop an irAE. This extended duration creates a correlation that may not be causal.
Rob points out all three chemo-IO trials raised pathological complete response by roughly 8-10%, yet only Niagara improved survival. He says path CR is not clinically meaningful by itself and has never been proven as a surrogate for event-free or overall survival. So similar activity signals cannot explain divergent outcomes.
Developers often test novel agents in late-line settings because the control arm is weaker, increasing the statistical chance of success. However, this strategy may doom effective immunotherapies by testing them in biologically hostile, resistant tumors, masking their true potential.
In solid tumor immunotherapy, significant efficacy gains almost always correlate with increased toxicity. This study's claim of nearly doubled progression-free survival with identical toxicity rates is biologically implausible and was a primary reason for skepticism, even before analyzing the trial's methodology.
A significant criticism of the pivotal KEYNOTE-564 trial is that only half the patients in the control arm received standard-of-care immunotherapy upon relapse. This lack of subsequent optimal treatment complicates the interpretation of the overall survival benefit, raising questions about its true magnitude.
Even when trials like LITESPARK 022 and Keynote 564 use identical eligibility criteria, outdated staging systems result in patient populations with different underlying risks. This makes direct comparison of outcomes between trials, even for the same drug, an unfair and statistically flawed analysis that ignores the function of a control arm.
Re-analysis revealed the drug's efficacy was concentrated in patients 65 and younger, extending survival by 17.1 months. This effect was missed in the original trials because it was diluted by the non-responsive older population, whose declined immune systems could not fully engage with the treatment.
Experts believe the stark difference in complete response rates (5% vs 30%) between two major ADC trials is likely due to "noise"—variations in patient populations (e.g., more upper tract disease) and stricter central review criteria, rather than a fundamental difference in the therapies' effectiveness.